Hims & Hers Health (NYSE:HIMS) Stock Price Down 1.5% - Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares dropped 1.5% during mid-day trading on Monday . The company traded as low as $54.62 and last traded at $55.50. Approximately 9,006,004 shares traded hands during trading, a decline of 56% from the average daily volume of 20,688,896 shares. The stock had previously closed at $56.33.

Analysts Set New Price Targets

Several research firms recently commented on HIMS. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Morgan Stanley lowered their price target on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 29th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Leerink Partners lifted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Price Performance

The stock has a market cap of $12.35 billion, a price-to-earnings ratio of 125.35 and a beta of 2.09. The company's 50 day moving average is $43.29 and its 200 day moving average is $37.67.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. During the same period last year, the company posted $0.05 earnings per share. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the transaction, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at $5,900,796.90. The trade was a 42.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael Chi sold 5,100 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $56.00, for a total value of $285,600.00. Following the completion of the sale, the insider now owns 256,580 shares in the company, valued at $14,368,480. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 622,467 shares of company stock valued at $25,513,488. Insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC boosted its position in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after acquiring an additional 40,447 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.